Understanding The Role of CYP21A1P in Drug Metabolism and DILI

Target Name: CYP21A1P

NCBI ID: G1590

Other Name(s): P450c21A | CYP21P | CYP21A | Cytochrome P450 family 21 subfamily A member 1, pseudogene | cytochrome P450 family 21 subfamily A member 1, pseudogene

Understanding The Role of CYP21A1P in Drug Metabolism and DILI

CYP21A1P, also known as P450c21A, is a gene that encodes a protein known as CYP21A1P. This gene is located on chromosome 19 and encodes a protein that plays a critical role in the metabolism of drugs.

The CYP21A1P protein is a member of the cytochrome P450 (CYP) family of enzymes, which are responsible for metabolizing a wide variety of drugs and other substances in the body. These enzymes are found in every cell of the body and are responsible for breaking down the active ingredients of drugs in order to determine how much of the drug is removed from the body.

CYP21A1P is a potent enzyme that is involved in the metabolism of many different drugs, including some statins, antidepressants, and opioids. It is found in high concentrations in the liver and other organs, and is often used as a drug target or biomarker to study the effects of drugs on this enzyme.

One of the main reasons why CYP21A1P is a drug target is because it is involved in the metabolism of many different drugs that are used to treat a wide range of medical conditions. For example, some studies have found that drugs that are metabolized by CYP21A1P are more likely to cause side effects than drugs that are metabolized by other enzymes. Additionally, drugs that are metabolized by CYP21A1P may not be as effective as drugs that are metabolized by other enzymes, which could lead to a reduced treatment effect.

Another reason why CYP21A1P is a drug target is that it is a sensitive target for drug interactions. Many drugs that are used to treat different medical conditions can interact with CYP21A1P, which can lead to an increase or decrease in the amount of drug that is available in the body. This can have a significant impact on the effectiveness of the drug and may lead to unwanted side effects.

In addition to its role as a drug target, CYP21A1P is also a potential biomarker for drug-induced liver injury (DILI). DILI is a condition in which the liver is damaged as a result of the use of certain drugs, and is often treated with drugs that are metabolized by CYP21A1P. However, some studies have found that the levels of CYP21A1P in the liver can increase significantly in individuals who have been treated with drugs that are metabolized by this enzyme, which could be an indication of DILI.

Overall, CYP21A1P is a gene that is involved in the metabolism of many different drugs and has been identified as a potential drug target and biomarker for DILI. Further research is needed to fully understand the role of this enzyme in the body and to develop effective treatments for individuals who are affected by DILI.

Protein Name: Cytochrome P450 Family 21 Subfamily A Member 1, Pseudogene

More Common Targets